CBL-B Inhibitor-treated Autologous Tumor-infiltrating Lymphocytes DeTIL-0255

Preferred Label : CBL-B Inhibitor-treated Autologous Tumor-infiltrating Lymphocytes DeTIL-0255;

NCIt synonyms : Autologus TILs DeTIL-0255; NX-0255 Drug-enhanced TILs; DeTIL NX0255; DeTIL NX-0255; NX-0255-treated Autologous TILs DeTIL-0255;

NCIt definition : A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from a patient's tumor that have been treated ex vivo during cell expansion with NX-0255, an inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulating and antineoplastic activities. Upon administration, the CBL-B inhibitor-treated autologous TILs DeTIL-0255 specifically recognize and kill the patient's tumor cells. NX-0255 enhances TIL expansion and the tumor-killing ability of the TILs when returned to the patient.;

Molecule name : DeTIL-0255;

NCI Metathesaurus CUI : CL1773397;

Details

Origin ID

C185289;

UMLS CUI

C5666969;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients